POWERFUL NEWS:

MMRF PRESS RELEASES


Multiple Myeloma Research Foundation (MMRF) Launches Cutting-Edge, Personalized Clinical Trial Matching Service Powered by EmergingMed


NORWALK, Conn. — May 30, 2007
Features Clinical Trial Navigators to Facilitate Individualized Searches and Speed Accrual

The Multiple Myeloma Research Foundation (MMRF) and EmergingMed are pleased to announce the launch of the new MMRF Clinical Trial Matching Service. This highly personalized service, powered by EmergingMed, is available free to patients, physicians and caregivers both on the MMRF website and by calling a toll free phone number. The service enables visitors to learn about new multiple myeloma therapies in development and to easily identify and match to clinical trials for which they or their loved ones might be eligible, which will in turn lead to expedited enrollment to clinical trials, particularly for new therapies and combinations.

"This program exemplifies the MMRF's commitment to accelerating the development and availability of new treatments for cancer. Through this service, we are helping patients to more easily find treatments that are most appropriate for them," said Kathy Giusti, Founder and Chief Executive Officer of the MMRF, as well as a myeloma patient. "Currently, there are hundreds of clinical trials available for myeloma patients, many of which are novel therapies and combinations, and it is difficult to navigate through all of the options without expert assistance. With this program, we expect to see an increase in clinical trial participation and acceleration of clinical trial accrual."

Patients and visitors can access the MMRF Clinical Trial Matching Service by visiting www.themmrf.org and clicking on the "Find a Clinical Trial" button or by calling toll free 1.800.506.9044. Either online or by phone, visitors can learn about available clinical trials and, by filling out a simple questionnaire, can identify specific studies for which they may be eligible. All submitted information is kept strictly confidential. Within seconds, visitors can see the available treatment and supportive care clinical trials which match their profiles. Upon the patient's request, an EmergingMed Clinical Trial Specialist will help facilitate contact with the team and the site conducting the trials. The service responds to requests by phone or email the same day an application is submitted.

"EmergingMed shares MMRF's commitment to accelerating the search for a cure for multiple myeloma as well as other critical diseases by advancing new and improved treatments. Only by making it easier and simpler for patients to find and enroll in clinical trials will we be able to speed the process of developing new therapies for those who need them. EmergingMed's team of Clinical Trial Specialists are dedicated to providing personalized service, education and navigation support for patients and caregivers considering clinical trials as a treatment option," said Courtney Hudson, EmergingMed's President and CEO.

About Multiple Myeloma

Multiple myeloma, an incurable cancer of the plasma cell, is the second most common hematologic (blood) cancer, representing one percent of all cancer diagnoses and two percent of all cancer deaths. Despite recent advances in treating myeloma, the five-year survival rate for multiple myeloma is only 34 percent, one of the lowest of all cancers. Approximately 50,000 people in the United States are living with multiple myeloma and an estimated 20,000 new cases are diagnosed each year.

About the Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, a newly diagnosed multiple myeloma patient, with the unique mission of accelerating the search for a cure for multiple myeloma. As the world's number one funder of myeloma research, the MMRF has raised more than $75 million to fund more than 215 research grants at more than 75 research institutions around the globe. Currently, the MMRF is funding more than 30 new compounds and approaches - in pre-clinical testing and Phase I, II and III clinical trials - that show promise in treating patients at all stages of the disease. For more information about the MMRF, please visit www.themmrf.org.

About EmergingMed

EmergingMed was founded in January 2000 to provide patients, families and health care professionals with a fast and easy way to find and understand new therapies in development and to speed up drug development through increased enrollment in clinical trials. EmergingMed provides clinical trial information services for over 30 organizations, including the American Cancer Society, Lance Armstrong Foundation, Pfizer, Amgen, the Dana-Farber/Harvard Cancer Center, Ohio State University, and the State of Florida. For more information call 1.877.601.8601, visit www.emergingmed.com or write to BizDev@emergingmed.com.